Literature DB >> 17932770

The adrenal and polycystic ovary syndrome.

Bulent O Yildiz1, Ricardo Azziz.   

Abstract

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders characterized by androgen excess, oligo-ovulation and polycystic ovaries. Although ovaries are the main source of increased androgens in the syndrome, between 20 and 30% of patients with PCOS have adrenal androgen (AA) excess, detectable primarily by elevated dehydroepiandrosterone sulfate (DHEAS) levels. Patients with PCOS demonstrate a generalized hypersecretion of adrenocortical products, basally and in response to ACTH stimulation. The mechanisms of these abnormalities are unclear although AA excess in PCOS is likely a complex trait, modulated by both intrinsic and acquired factors. To date, no specific genetic defects have been identified. The production of AAs in response to ACTH appears to be closely related to altered factors regulating glucose-mediated glucose disposal, increased peripheral metabolism of cortisol, and to a less extent to the effects of extra-adrenal androgens, insulin resistance, hyperinsulinemia or obesity. Finally, DHEAS levels and the response of AAs to ACTH are relatively constant over time and are closely correlated between PCOS patients and their siblings suggesting that this abnormality is an inherited trait in PCOS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17932770     DOI: 10.1007/s11154-007-9054-0

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  101 in total

1.  Endogenous inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 do not explain abnormal cortisol metabolism in polycystic ovary syndrome.

Authors:  B R Walker; A Rodin; N F Taylor; R N Clayton
Journal:  Clin Endocrinol (Oxf)       Date:  2000-01       Impact factor: 3.478

2.  Aromatization of androstenedione to estrone by human adipose tissue in vitro. Correlation with adipose tissue mass, age, and endometrial neoplasia.

Authors:  J P Forney; L Milewich; G T Chen; J L Garlock; B E Schwarz; C D Edman; P C MacDonald
Journal:  J Clin Endocrinol Metab       Date:  1981-07       Impact factor: 5.958

3.  Hyperandrogenism in carriers of CYP21 mutations: the role of genotype.

Authors:  Osnat Admoni; Shosh Israel; Idit Lavi; Michal Gur; Yardena Tenenbaum-Rakover
Journal:  Clin Endocrinol (Oxf)       Date:  2006-06       Impact factor: 3.478

Review 4.  Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span.

Authors:  Ricardo Azziz; Catherine Marin; Lalima Hoq; Enkhe Badamgarav; Paul Song
Journal:  J Clin Endocrinol Metab       Date:  2005-06-08       Impact factor: 5.958

5.  Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS).

Authors:  Ashim Kumar; Keslie S Woods; Alfred A Bartolucci; Ricardo Azziz
Journal:  Clin Endocrinol (Oxf)       Date:  2005-06       Impact factor: 3.478

6.  Hyperinsulinemia and circulating dehydroepiandrosterone sulfate in white and Mexican American women with polycystic ovary syndrome.

Authors:  Robert P Kauffman; Vicki M Baker; Pamela DiMarino; V Daniel Castracane
Journal:  Fertil Steril       Date:  2006-04       Impact factor: 7.329

7.  The hormonal phenotype of Nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency.

Authors:  Goldy Carbunaru; Pallavi Prasad; Bert Scoccia; Patrick Shea; Nancy Hopwood; Fuad Ziai; Ying Tai Chang; Susan E Myers; J Ian Mason; Songya Pang
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

8.  Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency.

Authors:  Chantal Lutfallah; Weihua Wang; J Ian Mason; Ying Tai Chang; Anzar Haider; Barry Rich; Mariano Castro-Magana; Kenneth C Copeland; Raphael David; Songya Pang
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

9.  Increased urinary free cortisol and decreased serum corticosteroid-binding globulin in polycystic ovary syndrome.

Authors:  C Invitti; F Pecori Giraldi; A Dubini; M De Martin; F Cavagnini
Journal:  Acta Endocrinol (Copenh)       Date:  1991-07

10.  Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia?

Authors:  J H Levin; E Carmina; R A Lobo
Journal:  Fertil Steril       Date:  1991-10       Impact factor: 7.329

View more
  36 in total

Review 1.  Defining adrenarche in the rhesus macaque (Macaca mulatta), a non-human primate model for adrenal androgen secretion.

Authors:  A J Conley; B C Moeller; A D Nguyen; S D Stanley; T M Plant; D H Abbott
Journal:  Mol Cell Endocrinol       Date:  2010-12-22       Impact factor: 4.102

2.  RhoA and DIAPH1 mediate adrenocorticotropin-stimulated cortisol biosynthesis by regulating mitochondrial trafficking.

Authors:  Donghui Li; Marion B Sewer
Journal:  Endocrinology       Date:  2010-06-30       Impact factor: 4.736

Review 3.  Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.

Authors:  Stavroula A Paschou; Stergios A Polyzos; Panagiotis Anagnostis; Dimitrios G Goulis; Christina Kanaka-Gantenbein; Irene Lambrinoudaki; Neoklis A Georgopoulos; Andromachi Vryonidou
Journal:  Endocrine       Date:  2019-09-19       Impact factor: 3.633

4.  Acute serum hormone levels: characterization and prognosis after severe traumatic brain injury.

Authors:  Amy K Wagner; Emily H McCullough; Christian Niyonkuru; Haishin Ozawa; Tammy L Loucks; Julie A Dobos; Christopher A Brett; Martina Santarsieri; C Edward Dixon; Sarah L Berga; Anthony Fabio
Journal:  J Neurotrauma       Date:  2011-06-01       Impact factor: 5.269

5.  Developmental programming: impact of excess prenatal testosterone on intrauterine fetal endocrine milieu and growth in sheep.

Authors:  Almudena Veiga-Lopez; Teresa L Steckler; David H Abbott; Kathleen B Welch; Puliyur S MohanKumar; David J Phillips; Kent Refsal; Vasantha Padmanabhan
Journal:  Biol Reprod       Date:  2010-08-25       Impact factor: 4.285

Review 6.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

7.  Revisiting hyper- and hypo-androgenism by tandem mass spectrometry.

Authors:  Flaminia Fanelli; Alessandra Gambineri; Marco Mezzullo; Valentina Vicennati; Carla Pelusi; Renato Pasquali; Uberto Pagotto
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

8.  Glucosamine inhibits decidualization of human endometrial stromal cells and decreases litter sizes in mice.

Authors:  Jui-He Tsai; Maureen Schulte; Kathleen O'Neill; Maggie M-Y Chi; Antonina I Frolova; Kelle H Moley
Journal:  Biol Reprod       Date:  2013-07-25       Impact factor: 4.285

Review 9.  Ontogeny of the ovary in polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Joanne S Richards
Journal:  Fertil Steril       Date:  2013-03-06       Impact factor: 7.329

Review 10.  Nonhuman primates as models for human adrenal androgen production: function and dysfunction.

Authors:  D H Abbott; I M Bird
Journal:  Rev Endocr Metab Disord       Date:  2009-03       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.